Unknown

Dataset Information

0

Canine Adipose-Derived Mesenchymal Stem Cells (cAdMSCs) as a "Trojan Horse" in Vaccinia Virus Mediated Oncolytic Therapy against Canine Soft Tissue Sarcomas.


ABSTRACT: Several oncolytic viruses (OVs) including various human and canine adenoviruses, canine distemper virus, herpes-simplex virus, reovirus, and members of the poxvirus family, such as vaccinia virus and myxoma virus, have been successfully tested for canine cancer therapy in preclinical and clinical settings. The success of the cancer virotherapy is dependent on the ability of oncolytic viruses to overcome the attacks of the host immune system, to preferentially infect and lyse cancer cells, and to initiate tumor-specific immunity. To date, several different strategies have been developed to overcome the antiviral host defense barriers. In our study, we used canine adipose-derived mesenchymal stem cells (cAdMSCs) as a "Trojan horse" for the delivery of oncolytic vaccinia virus Copenhagen strain to achieve maximum oncolysis against canine soft tissue sarcoma (CSTS) tumors. A single systemic administration of vaccinia virus-loaded cAdMSCs was found to be safe and led to the significant reduction and substantial inhibition of tumor growth in a CSTS xenograft mouse model. This is the first example that vaccinia virus-loaded cAdMSCs could serve as a therapeutic agent against CSTS tumors.

SUBMITTER: Petrov I 

PROVIDER: S-EPMC7411685 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Canine Adipose-Derived Mesenchymal Stem Cells (cAdMSCs) as a "Trojan Horse" in Vaccinia Virus Mediated Oncolytic Therapy against Canine Soft Tissue Sarcomas.

Petrov Ivan I   Gentschev Ivaylo I   Vyalkova Anna A   Elashry Mohamed I MI   Klymiuk Michele C MC   Arnhold Stefan S   Szalay Aladar A AA  

Viruses 20200712 7


Several oncolytic viruses (OVs) including various human and canine adenoviruses, canine distemper virus, herpes-simplex virus, reovirus, and members of the poxvirus family, such as vaccinia virus and myxoma virus, have been successfully tested for canine cancer therapy in preclinical and clinical settings. The success of the cancer virotherapy is dependent on the ability of oncolytic viruses to overcome the attacks of the host immune system, to preferentially infect and lyse cancer cells, and to  ...[more]

Similar Datasets

| S-EPMC3352892 | biostudies-literature
2023-07-05 | GSE214154 | GEO
| S-EPMC3810003 | biostudies-literature
| S-EPMC5704538 | biostudies-literature
| S-EPMC5035934 | biostudies-literature
| S-EPMC4344612 | biostudies-literature
| PRJNA884145 | ENA
| S-EPMC10052453 | biostudies-literature
| S-EPMC4501768 | biostudies-literature
| S-EPMC6522548 | biostudies-literature